The MDS Beacon is planning to report on progress made in 2012...
"The 54th annual meeting of the American Society of Hematology will be held this Saturday, December 8, through Tuesday, December 11, in Atlanta.
Over 20,000 people are expected to attend this year’s meeting, where experts from around the world will gather to discuss current research regarding the diagnosis and treatment of various blood diseases, including myelodysplastic syndromes (MDS).
The American Society of Hematology (ASH) meeting includes education and scientific sessions, poster viewings, and oral presentations, as well as meet-the-expert opportunities.
The latest MDS research findings will be discussed in over 100 oral presentations and more than 300 posters. In addition, the meeting features a few education programs on MDS-specific topics..."
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%
)
47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).